Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20029212 | 0.87 | SCD (0.47) | ROCK2SCDRIPK1MGLL | |
| SCHEMBL23075395 | 0.85 | TBXAS1 (0.43) | GPR119SCDRIPK1NAMPTGRM1 | |
| SCHEMBL29926795 | 0.85 | TBXAS1 (0.43) | GPR119SCDRIPK1NAMPTGRM1 | |
| SCHEMBL23076353 | 0.85 | KDM1A (0.40) | CYP17A1ROCK2SCDRIPK1 | |
| SCHEMBL31402975 | 0.82 | GPR119 (0.48) | GPR119 | |
| SCHEMBL28719588 | 0.82 | GPR119 (0.45) | GPR119ROCK2 | |
| SCHEMBL1844348 | 0.81 | ROCK2 (0.41) | GPR119ROCK2SCDMGLL | |
| SCHEMBL21121081 | 0.81 | ROCK2 (0.41) | GPR119ROCK2SCDMGLL | |
| SCHEMBL18617132 | 0.81 | ROCK2 (0.41) | GPR119ROCK2SCDMGLL | |
| SCHEMBL429428 | 0.80 | ROCK2 (0.43) | GPR119ROCK2SCDMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331036-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4025572-B1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-114761398-B | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117083270-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11479543-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-09-22 | — | — | US | disclosed |
| WO-2022192533-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-114761398-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046447-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479543-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | CYP17A1 4386/4885GPR119 1156/4885ROCK2 326/4885 |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | CYP17A1 4386/4885GPR119 1156/4885ROCK2 326/4885 |
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | CYP17A1 4386/4885GPR119 1156/4885ROCK2 326/4885 |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | CYP17A1 4386/4885GPR119 1156/4885ROCK2 326/4885 |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | CYP17A1 4386/4885GPR119 1156/4885ROCK2 326/4885 |
| US-12331036-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | CYP17A1 4386/4885GPR119 1156/4885ROCK2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.